Table 2.
Change ratio in biomarkers between the luseogliflozin and voglibose groups.
| Variables | Ratio of change from the baseline | p value | |
|---|---|---|---|
| Luseogliflozin group (n = 79) | Voglibose group (n = 78) | ||
| Atherogenic lipid | |||
| MDA-LDL, % | 0.2 (− 5.6 to 6.3) | − 0.6 (− 7.8 to 7.1) | 0.93 |
| Small-dense LDL cholesterol, % | − 1.7 (− 7.4 to 4.3) | − 8.6 (− 15.5 to − 1.1) | 0.21 |
| Inflammatory marker | |||
| Adiponectin, % | − 1.6 (− 5.4 to 2.4) | − 4.0 (− 9.0 to 1.3) | 0.52 |
| High-sensitivity CRP, % | 22.5 (− 1.6 to 52.5) | 10.0 (− 18.1 to 47.7) | 0.55 |
| Other lipid profile | |||
| Total cholesterol, % | |||
| Week 4 | 1.3 (− 1.5 to 4.1) | − 4.4 (− 7.1 to − 1.8) | 0.009 |
| Week 12 | 1.6 (− 2.6 to 5.7) | − 5.3 (− 9.3 to − 1.3) | 0.02 |
| Week 24 | 1.1 (− 2.3 to 4.5) | − 2.0 (− 5.9 to 1.9) | 0.19 |
| HDL cholesterol, % | |||
| Week 4 | 0.2 (− 3.4 to 3.8) | − 5.0 (− 7.4 to − 2.6) | 0.02 |
| Week 12 | 2.4 (− 2.6 to 7.4) | − 4.7 (− 9.1 to − 0.3) | 0.04 |
| Week 24 | 3.4 (− 1.0 to 7.7) | 1.4 (− 2.4 to 5.2) | 0.43 |
| LDL cholesterol, % | |||
| Week 4 | 31.5 (− 21.8 to 84.8) | − 3.9 (− 9.2 to 1.4) | 0.17 |
| Week 12 | 13.2 (− 5.4 to 31.9) | − 2.6 (− 8.9 to 3.7) | 0.14 |
| Week 24 | 23.2 (23.0 to 69.3) | − 0.4 (− 6.9 to 5.9) | 0.25 |
| Triglyceride, % | |||
| Week 4 | − 2.6 (− 11.5 to 7.11) | − 3.2 (− 10.4 to 4.5) | 0.65 |
| Week 12 | − 1.3 (− 11.7 to 10.3) | − 8.9 (− 17.2 to 0.2) | 0.28 |
| Week 24 | − 0.3 (− 11.9 to 12.7) | − 7.8 (− 15.3 to 1.27) | 0.52 |
Data are presented as the mean (95% confidence interval).
CRP C-reactive protein, HDL high-density lipoprotein, MDA-LDL malondialdehyde low-density lipoprotein.